- Profile
- prev
- next
General
-
Headquarters
Seattle, Washington, United States
-
Founders & Team
Gary Hudson, Matt Scholz
-
Year Founded
2014
-
Company type
Private company
-
Funding stage
Seed
-
Total funding ($M)
2.1
-
Investors
Kizoo Technology Capital, Kingsley Advani
Technical Details
-
Aging Target
Cellular senescence
-
Disease indication
Kidney disease
-
Product modality
gene therapy
-
Clinical stage
Pre-clinical
About us
Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age related diseases. When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function. Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases. Oisín Biotechnologies is developing a highly precise, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.